{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:07:08Z","timestamp":1785424028272,"version":"3.56.0"},"reference-count":18,"publisher":"Akademiai Kiado Zrt.","issue":"29","content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2025,7,20]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    Az orrpolippal k\u00eds\u00e9rt kr\u00f3nikus rhinosinusitis\n                    domin\u00e1l\u00f3an T2-es t\u00edpus\u00fa immunpatol\u00f3giai betegs\u00e9g, amely a t\u00fcneti gy\u00f3gyszeres \u00e9s\n                    seb\u00e9szi kezel\u00e9s ellen\u00e9re sz\u00e1mos esetben tart\u00f3s \u00e9letmin\u0151s\u00e9g-roml\u00e1ssal j\u00e1r egy\u00fctt.\n                    A nehezen kezelhet\u0151 endot\u00edpusok gy\u00f3gy\u00edt\u00e1s\u00e1ban hatalmas el\u0151rel\u00e9p\u00e9s a biol\u00f3giai\n                    ter\u00e1pia. Az els\u0151nek v\u00e1lasztand\u00f3 dupilumabbal haz\u00e1nkban \u00f6t\u00e9ves tapasztalatok\n                    \u00e1llnak rendelkez\u00e9sre.\n                    <jats:italic>M\u00f3dszer:<\/jats:italic>\n                    A k\u00e9tcentrumos retrospekt\u00edv\n                    vizsg\u00e1latba 137 beteget v\u00e1lasztottunk be, akiket 2020. okt\u00f3ber \u00e9s 2025. janu\u00e1r\n                    k\u00f6z\u00f6tt dupilumabbal kezelt\u00fcnk; k\u00f6z\u00fcl\u00fck 107 beteg legal\u00e1bb f\u00e9l\u00e9ves\n                    kontrollvizsg\u00e1lati adat\u00e1val rendelkez\u00fcnk. A szakmai el\u0151\u00edr\u00e1soknak megfelel\u0151en a\n                    g\u00e1tolt orrl\u00e9gz\u00e9s m\u00e9rt\u00e9k\u00e9t vizu\u00e1lis anal\u00f3g sk\u00e1l\u00e1val, az orrpolip kiterjed\u00e9s\u00e9t\n                    endoszk\u00f3ppal, a szagl\u00e1scs\u00f6kken\u00e9st t\u00fcneti pontsz\u00e1mmal, az \u00e9letmin\u0151s\u00e9get\n                    specifikus k\u00e9rd\u0151\u00edv seg\u00edts\u00e9g\u00e9vel vizsg\u00e1ltuk.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    A\n                    kezel\u00e9si id\u0151tartam \u00e1tlaga 554,6 \u00b1 355,3 nap; 6 beteget t\u00f6bb mint n\u00e9gy, 16-ot\n                    t\u00f6bb mint h\u00e1rom, 54-et t\u00f6bb mint k\u00e9t \u00e9ve kezel\u00fcnk, \u00e9s 104 beteg ter\u00e1pi\u00e1ja egy\n                    \u00e9vn\u00e9l r\u00e9gebben kezd\u0151d\u00f6tt. A T2-es k\u00eds\u00e9r\u0151 betegs\u00e9gek ar\u00e1nya a k\u00f6vetkez\u0151k\u00e9ppen\n                    alakult: asthma 105 (76,64%), nemszteroid gyullad\u00e1scs\u00f6kkent\u0151 ir\u00e1nti intolerancia\n                    63 (45,99%), allergi\u00e1s rhinitis 69 (50,36%) esetben ker\u00fclt meg\u00e1llap\u00edt\u00e1sra. A\n                    betegek vizsg\u00e1lt param\u00e9terei a kiindul\u00e1si \u00e9rt\u00e9kekhez viszony\u00edtva minden\n                    id\u0151pontban szignifik\u00e1ns m\u00e9rt\u00e9kben (p&lt;0,001) javultak. Az \u00e9letmin\u0151s\u00e9get\n                    jelent\u0151s m\u00e9rt\u00e9kben befoly\u00e1sol\u00f3 szagl\u00e1scs\u00f6kken\u00e9s 71,96%-ban kifejezett m\u00e9rt\u00e9kben\n                    javult. 25 esetben (23,36%) \u00e9szlelt\u00fcnk mell\u00e9khat\u00e1sokat, 5 betegn\u00e9l (3,65%) a\n                    ter\u00e1pia felf\u00fcggeszt\u00e9sre ker\u00fclt. A leggyakrabban tapasztalt mell\u00e9khat\u00e1sok a\n                    k\u00f6vetkez\u0151k voltak: \u00edz\u00fcleti f\u00e1jdalmak \u00e9s megemelkedett sz\u00e9rum-eosinophilsejtsz\u00e1m\n                    (8-8 eset), valamint b\u0151r- \u00e9s ny\u00e1lkah\u00e1rtya-elv\u00e1ltoz\u00e1sok (n = 7). A p\u00e1ciensek\n                    27%-\u00e1ban a dupilumab d\u00f3zis\u00e1t \u00fagy lehetett cs\u00f6kkenteni, hogy a hat\u00e9konys\u00e1g nem\n                    v\u00e1ltozott.\n                    <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    Hossz\u00fa t\u00e1v\u00fa ut\u00e1nk\u00f6vet\u00e9ses\n                    vizsg\u00e1latunk sor\u00e1n nagy betegsz\u00e1mon igazolni tudtuk, hogy a dupilumab a\n                    konvencion\u00e1lis kezel\u00e9sn\u00e9l l\u00e9nyegesen hat\u00e9konyabb \u00e9s a kezel\u00e9si elvek betart\u00e1sa\n                    eset\u00e9n biztons\u00e1gos. Orv Hetil. 2025; 166(29): 1123\u20131131.\n                  <\/jats:p>","DOI":"10.1556\/650.2025.33356","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T04:43:54Z","timestamp":1753073034000},"page":"1123-1131","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["A kr\u00f3nikus rhinosinusitis orrpolipos form\u00e1j\u00e1nak dupilumabkezel\u00e9ssel szerzett hossz\u00fa t\u00e1v\u00fa tapasztalatai"],"prefix":"10.1556","volume":"166","author":[{"given":"Andor","family":"Hirschberg","sequence":"first","affiliation":[{"name":"\u00c9szak-budai Szent J\u00e1nos Centrumk\u00f3rh\u00e1z, F\u00fcl-Orr-G\u00e9ge \u00e9s Sz\u00e1jseb\u00e9szeti Oszt\u00e1ly Budapest, Di\u00f3s \u00e1rok 1\u20133., 1125 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ria","family":"Matuz","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Gy\u00f3gyszer\u00e9sz-tudom\u00e1nyi Kar Szentgy\u00f6rgyi Albert Klinikai K\u00f6zpont, Klinikai Gy\u00f3gyszer\u00e9szeti Int\u00e9zet; Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Kiricsi","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, F\u00fcl-Orr-G\u00e9g\u00e9szeti \u00e9s Fej-Nyakseb\u00e9szeti Klinika Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Hirschberg A. Biological therapy in the inflammatory disorders of\n                    the upper airway: the endotype-driven treatment of chronic rhinosinusitis.\n                    [Biol\u00f3giai ter\u00e1pia a fels\u0151 l\u00e9g\u00fati gyullad\u00e1sos betegs\u00e9gekben: az endot\u00edpus-alap\u00fa\n                    megk\u00f6zel\u00edt\u00e9s a kr\u00f3nikus rhinosinusitis kezel\u00e9s\u00e9ben.] Orv Hetil. 2023; 164:\n                    694\u2013701. [Hungarian]","DOI":"10.1556\/650.2023.32792"},{"key":"R2","unstructured":"Hirschberg A, Lujber L, Bella Zs. Hungarian protocol for the chronic\n                    rhinosinusitis (CRS). [Az Emberi Ero\u030bforra\u0301sok Miniszte\u0301riuma ege\u0301szse\u0301gu\u0308gyi\n                    szakmai ira\u0301nyelve a kro\u0301nikus rhinosinusitisro\u030bl (CRS).] E\u00fc K\u00f6zl. 2022; 72 (7):\n                    1157\u20131207. [Hungarian]"},{"key":"R3","unstructured":"Hirschberg A, T\u00f3th L, Helfferich F, et al. Hungarian protocol for\n                    the indications of biological therapy and method of follow-up in the type of\n                    bilateral diffuse nasal polyposis of chronic rhinosinusitis. [A biol\u00f3giai\n                    kezel\u00e9s indik\u00e1ci\u00f3i \u00e9s a betegk\u00f6vet\u00e9s m\u00f3dszertana a kr\u00f3nikus rhinosinusitis\n                    k\u00e9toldali, diff\u00faz orrpolip\u00f3zissal k\u00eds\u00e9rt fenot\u00edpus\u00e1ban. Az Eg\u00e9szs\u00e9g\u00fcgyi Szakmai\n                    Koll\u00e9gium F\u00fcl-orr-g\u00e9g\u00e9szet Tagozat\u00e1nak szakmai \u00e1ll\u00e1sfoglal\u00e1sa.]\n                    F\u00fcl-Orr-G\u00e9gegy\u00f3gy\u00e1szat 2021; 67: 55\u201360. [Hungarian]"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Kiricsi A, Bella Zs, Kraxner H, et al. Real-life effectiveness of\n                    dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight\n                    Hungarian centres with 12-month follow-up. Rhinology 2024; 62:\n                    410\u2013420.","DOI":"10.4193\/Rhin23.278"},{"key":"R5","unstructured":"Hirschberg A, Kiricsi \u00c1. First Hungarian experiences with biological\n                    therapy and proposed protocol in chronic rhinosinusitis with nasal polyp type 2.\n                    [A biol\u00f3giai ter\u00e1pia kezdeti hazai tapasztalatai \u00e9s kezel\u00e9si\n                    elj\u00e1r\u00e1srend-javaslat 2-es t\u00edpus\u00fa, orrpolippal j\u00e1r\u00f3 kr\u00f3nikus rhinosinusitisben.]\n                    F\u00fcl-Orr-G\u00e9gegy\u00f3gy\u00e1szat 2024; 70: 5\u201310. [Hungarian]"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Viskens AS, Backer B, et al. EPOS\/EUFOREA update on\n                    indication and evaluation of biologics in chronic rhinosinusitis with nasal\n                    polyps. Rhinology 2023; 61: 194\u2013202.","DOI":"10.4193\/Rhin22.489"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on\n                    Rhinosinusitis and Nasal Polyps 2020 (EPOS2020). Rhinology 2020; 58(Suppl 29):\n                    1\u2013464.","DOI":"10.4193\/Rhin20.401"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Hopkins C, Gillett S, Slack R, et al. Psychometric validity of the\n                    22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009; 34:\n                    447\u2013454.","DOI":"10.1111\/j.1749-4486.2009.01995.x"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of\n                    dupilumab in patients with severe chronic rhinosinusitis with nasal polyps\n                    (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre,\n                    randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.\n                    Lancet 2019; 394: 1638\u20131650. Erratum: Lancet 2019; 394: 1618.","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"De Corso E, Pasquini E, Trimarchi M, et al. Dupilumab in the\n                    treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps\n                    (CRSwNP): a multicentric observational Phase IV real-life study (DUPIREAL).\n                    Allergy 2023; 78: 2669\u20132683.","DOI":"10.1111\/all.15772"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Sedaghat A, Soyka M, et al. Recent advances in chronic\n                    rhinosinusitis: pathophysiology, treatments, and outcome measures. Rhinology\n                    2024; 62: 652\u2013658.","DOI":"10.4193\/Rhin24.801"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Mauthe T, Ryser FS, Br\u00fchlmann C, et al. Correlation of sino-nasal\n                    outcome test and nasal polyp score in dupilumab-treated chronic rhinosinusitis\n                    with nasal polyps. Eur Arch Otorhinolaryngol. 2025; 282:\n                    207\u2013218.","DOI":"10.1007\/s00405-024-08973-7"},{"key":"R13","unstructured":"Global Initiative for Asthma. Global strategy for asthma management\n                    and prevention, 2024. Available from:\n                    https:\/\/ginasthma.org\/reports\/."},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, De Corso E, Backer V, et al. EPOS2020\/EUFOREA expert\n                    opinion on defining disease states and therapeutic goals in CRSwNP. Rhinology\n                    2024; 62: 287\u2013298.","DOI":"10.4193\/Rhin23.415"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Rosso C, De Corso E, Urbanelli A, et al. Changes in weight secondary\n                    to improved odor perception in chronic rhinosinusitis with nasal polyps\u2019\n                    patients treated with dupilumab. Eur Arch Otorhinolaryngol. 2025; 282:\n                    251\u2013256.","DOI":"10.1007\/s00405-024-09021-0"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"van der Lans RJ, Otten JJ, Adriaensen GF, et al. Two-year results of\n                    tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the\n                    first 6\u2009months. Allergy 2023; 78: 2684\u20132697.","DOI":"10.1111\/all.15796"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Ho YT, Wang HS, Lee TJ, et al. Postoperative adjuvant dupilumab\n                    improved immediate recovery in patients with advanced type 2 chronic\n                    rhinosinusitis: an exploratory pilot study. Int Forum Allergy Rhinol. 2025; 15:\n                    455\u2013459.","DOI":"10.1002\/alr.23523"},{"key":"R18","doi-asserted-by":"publisher","unstructured":"Orlando P, Licci G, Illiano G, et al. Sustained efficacy and low\n                    rate of adverse events of dupilumab in type-2 CRSwNP over 48 months.\n                    Laryngoscope 2025 Apr 23. 10.1002\/lary.32205.\n                    [Epub ahead of print]","DOI":"10.1002\/lary.32205"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/29\/article-p1123.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/29\/article-p1123.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/29\/article-p1123.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:53:07Z","timestamp":1785423187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/29\/article-p1123.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":18,"journal-issue":{"issue":"29"},"URL":"https:\/\/doi.org\/10.1556\/650.2025.33356","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]}}}